Evidence map›Paper›PMID 35333353›Full record

ArticleHuman molecular genetics2022

XBP1 variant 1 promotes mitosis of cancer cells involving upregulation of the polyglutamylase TTLL6.

Yongwang Zhong, Wenjing Yan, Jingjing Ruan, Mike Fang, Changjun Yu, Shaojun Du, Ganesha Rai, Dingyin Tao, Mark J Henderson, Shengyun Fang

Open access · greenAbstract read
In one paragraph

Article in Human molecular genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yongwang ZhongCenter for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Wenjing YanCenter for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jingjing RuanCenter for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Mike FangPopulation and Quantitative Health Sciences Department, Case Western Reserve University, Cleveland, OH 44106, USA.
Changjun YuDepartment of General surgery, Anhui Medical University First Affiliated Hospital, Hefei, Anhui 230032, China.
Shaojun DuDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Ganesha RaiNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Dingyin TaoNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Mark J HendersonNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Shengyun FangCenter for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0001-7280-5463
University of Maryland, Baltimore · USNational Institutes of Health · USAnhui Medical University · CNCase Western Reserve University · US

Funding

Analytical ChemistryZICTR000037 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI LECLAIR, CHRISTOPHER ARTHUR · 2015 to 2025
$23.2M
Pharmacologic enhancement of UBA1 activity in models of VEXAS syndromeU01AR081599 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI Shengyun Fang · 2022 to 2026
$1.9M
High-Content Screening to Identify Small Molecules for Refolding SOD1 MutantsU01GM117175 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI FANG, SHENGYUN · 2017 to 2019
$1.1M
NIAMS NIH HHS U01 AR081599NIGMS NIH HHS U01 GM117175
6 · The paper itself

Abstract

XBP1 variant 1 (Xv1) is the most abundant XBP1 variant and is highly enriched across cancer types but nearly none in normal tissues. Its expression is associated with poor patients' survival and is specifically required for survival of malignant cells, but the underlying mechanism is not known. Here we report that Xv1 upregulates the polyglutamylase tubulin tyrosine ligase-like 6 (TTLL6) and promotes mitosis of cancer cells. Like the canonical XBP1, Xv1 mRNA undergoes unconventional splicing by IRE1α under endoplasmic reticulum stress, but it is also constitutively spliced by IRE1β. The spliced Xv1 mRNA encodes the active form of Xv1 protein (Xv1s). RNA sequencing in HeLa cells revealed that Xv1s overexpression regulates expression of genes that are not involved in the canonical unfolded protein response, including TTLL6 as a highly upregulated gene. Gel shift assay and chromatin immunoprecipitation revealed that Xv1s bind to the TTLL6 promoter region. Knockdown of TTLL6 caused death of cancer cells but not benign and normal cells, similar to the effects of knocking down Xv1. Moreover, overexpression of TTLL6 partially rescued BT474 cells from apoptosis induced by either TTLL6 or Xv1 knockdown, supporting TTLL6 as an essential downstream effector of Xv1 in regulating cancer cell survival. TTLL6 is localized in the mitotic spindle of cancer cells. Xv1 or TTLL6 knockdown resulted in decreased spindle polyglutamylation and interpolar spindle, as well as congression failure, mitotic arrest and cell death. These findings suggest that Xv1 is essential for cancer cell mitosis, which is mediated, at least in part, by increasing TTLL6 expression.

Indexed as

EndoribonucleasesNeoplasmsEndoplasmic Reticulum StressHeLa CellsHumansMitosisPeptide SynthasesProtein Serine-Threonine KinasesRNA, MessengerUp-RegulationX-Box Binding Protein 1EndoribonucleasesPeptide SynthasesProtein Serine-Threonine KinasesRNA, MessengerTTLL6 protein, humanX-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID35333353
PMCPMC9396943
OpenAlexW4205547858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.